<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01005238</url>
  </required_header>
  <id_info>
    <org_study_id>SASL28</org_study_id>
    <nct_id>NCT01005238</nct_id>
  </id_info>
  <brief_title>Telbivudine Versus Lamivudine for Maintenance Therapy of Patients With Chronic Hepatitis B and Negative HBV Viral Load After 6 Month of Treatment With Telbivudine</brief_title>
  <acronym>SASL28</acronym>
  <official_title>A Randomized Open Label Study Evaluating the Efficacy of Continuous Telbivudine Versus Lamivudine in Patients With HBeAg-negative Chronic Hepatitis B Who Had Previously Achieved an Undetectable Viral Load During 24 Weeks of Telbivudine Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this randomized clinical study is to show non-inferiority of a change of&#xD;
      anti-viral therapy from telbivudine to lamivudine in patients who have achieved an&#xD;
      undetectable viral load at week 24 of telbivudine therapy compared to continuous treatment&#xD;
      with telbivudine with respect to the viral breakthrough rate at week 108 as the primary&#xD;
      clinical outcome.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    unsufficient patient recruitment&#xD;
  </why_stopped>
  <start_date>September 2009</start_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint is the rate of viral breakthrough during treatment defined as an increase of the viral titer to &gt; 200 IU/mL.</measure>
    <time_frame>The primary efficacy endpoint is the rate of viral breakthrough at week 108.</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Hepatitis, Chronic</condition>
  <arm_group>
    <arm_group_label>telbivudine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients in this arm will continue to take telbivudine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>lamivudine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients in this arm will take lamivudine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine</intervention_name>
    <arm_group_label>lamivudine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telbivudine</intervention_name>
    <arm_group_label>telbivudine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patients, &gt; 18 (having completed their 18th birthday). There is no&#xD;
             upper limit of age&#xD;
&#xD;
          -  Documented HBeAg negative CHB&#xD;
&#xD;
          -  HBsAg positive &gt; 6 months&#xD;
&#xD;
          -  HBV DNA &gt; 2000 IU/mL&#xD;
&#xD;
          -  Patient is willing and able to comply with the study drug regimen and all other study&#xD;
             requirements.&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Anti-viral HBV treatment naïve or previous treatment with interferon-alpha or&#xD;
             pegylated interferon-alpha stopped at least 1 month prior to screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Decompensated liver cirrhosis according to the judgment of the local investigator&#xD;
&#xD;
          -  Hepatocellular carcinoma&#xD;
&#xD;
          -  History of or laboratory signs of co-infection with HIV or HCV, HDV&#xD;
&#xD;
          -  Previous treatment with anti-viral drugs (previous treatment with interferon-α or&#xD;
             pegylated interferon-α is not an exclusion criteria, but has to be stopped one month&#xD;
             before screening)&#xD;
&#xD;
          -  History of hypersensitivity to any of the study drugs or to drugs with similar&#xD;
             chemical structures or their excipients&#xD;
&#xD;
          -  Any medical condition that requires frequent or prolonged use of systemic&#xD;
             corticosteroids (inhaled, topic or intra-articular corticosteroids are allowed)&#xD;
&#xD;
          -  Any medical condition requiring the chronic or prolonged use of potentially&#xD;
             hepatotoxic drugs or nephrotoxic drugs.&#xD;
&#xD;
          -  Current abuse of alcohol or illicit drugs.&#xD;
&#xD;
          -  Use of other investigational drugs at the time of randomization, or within 30 days or&#xD;
             5 half-lives of enrollment, whichever is longer.&#xD;
&#xD;
          -  Any other concurrent medical or social condition which is, in the opinion of the&#xD;
             investigator, likely to preclude compliance with the schedule of evaluations in the&#xD;
             protocol, or likely to confound the efficacy or safety observations of the study.&#xD;
&#xD;
          -  Any of the following laboratory values during Screening:&#xD;
&#xD;
               -  Hemoglobin (HGB) &lt;11 g/dL for men or &lt;10 g/dL for women&#xD;
&#xD;
               -  Total WBC &lt;3000/mm3&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) &lt;1,500.mm3&#xD;
&#xD;
               -  Platelet count &lt;50'000/mm3&#xD;
&#xD;
               -  Serum amylase or lipase ≥ 1.5 x ULN&#xD;
&#xD;
               -  Serum albumin &lt;3 g/dL&#xD;
&#xD;
               -  Total bilirubin &gt; 51 μmol/L (&gt; 3.0 mg/dL)&#xD;
&#xD;
               -  Estimated calculated serum creatinine clearance &lt; 50 mL/min using the&#xD;
                  Cockcroft-Gault method using actual or ideal body weight whichever is less&#xD;
                  (Cockcroft and Gault 1976)&#xD;
&#xD;
               -  AFP (alpha-fetoprotein) &gt; 100 ng/mL&#xD;
&#xD;
               -  ALT &gt; 10x ULN&#xD;
&#xD;
          -  Women who are pregnant or breastfeeding. Women of childbearing potential must have a&#xD;
             negative serum beta-human chorionic gonadotropin (β-HCG) during Screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Markus Heim, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Basel, Switzerland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>October 29, 2009</study_first_submitted>
  <study_first_submitted_qc>October 29, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 30, 2009</study_first_posted>
  <last_update_submitted>March 9, 2015</last_update_submitted>
  <last_update_submitted_qc>March 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Telbivudine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

